Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 29, 2022
Daily News
September 29, 2022
- Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
September 29, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
- Yakult Honsha Pulls NDA for Blood Cancer Med Duvelisib in Japan
September 29, 2022
- Taisho Files Autoinjector Version of RA Med Nanozora in Japan
September 29, 2022
- Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
- Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
- Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…